UPEXI INC
For the period ended Jun 30, 2024. Filed Dec 16, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Dec 16, 2024
UPXI$0.62-6.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
UPEXI, INC.
CONSOLIDATED STATEMENTS OF CASH FLOW
| Year ended June 30, | ||||
|---|---|---|---|---|
| 2024 · 2023 | ||||
| Cash flows from operating activities | ||||
| Net loss from operations | $(23,658,438) | $(16,930,289) | ||
| Adjustments to reconcile net loss from continuing operations to net cash (used in) provided by operating activities: | ||||
| Depreciation and amortization | 3,678,786 | 3,481,748 | ||
| Non-cash loss on the sale of Infusionz and select assets, net | - | 2,212,542 | ||
| Gain on the sale of VitaMedica and income from discontinued operations | (1,948,538) | - | ||
| Loss on the sale of New England Technology | 1,737,326 | - | ||
| Amortization of loan costs | 115,787 | 62,408 | ||
| Amortization of consideration discount | 1,112,676 | 969,098 | ||
| Impairment of goodwill and intangible assets | 7,869,425 | 3,746,301 | ||
| Inventory write-offs | 1,812,319 | 118,990 | ||
| Loss on impairment of building | 336,434 | - | ||
| Loss on sale of assets related to relocation of facility | 569,195 | |||
| Gain on sale of interactive offers | (237,670) | - | ||
| Change in deferred tax asset | (344,802) | (3,139,227) | ||
| Noncontrolling interest | - | (559,967) | ||
| Change in derivative | - | 1,770 | ||
| Stock based compensation | 1,169,843 | 3,664,538 | ||
| Changes in assets and liabilities, net of acquired amounts | ||||
| Accounts receivable | 675,709 | (364,665) | ||
| Inventory | 2,651,252 | (1,366,269) | ||
| Prepaid expenses and other assets | 106,610 | 287,797 | ||
| Operating lease payable | 302,050 | 4,238 | ||
| Accounts payable and accrued liabilities | (944,020) | 389,458 | ||
| Deferred revenue | 101,305 | - | ||
| Net cash used in operating activities - Continuing Operations | (4,894,751) | (7,421,529) | ||
| Net cash provided by operating activities - Discontinued Operations | 4,793,374 | 7,624,206 | ||
| Net cash (used in) provided by operating activities | (101,377) | 202,677 | ||
| Cash flows from investing activities | ||||
| Acquisition of Lucky Tail | - | (3,528,239) | ||
| Proceeds from the sale of VitaMedica, Inc. | 2,100,000 | - | ||
| Proceeds from the sale of Interactive Offers, net of liabilities paid | 203,025 | - | ||
| Acquisition of Cygnet Online LLC, net | (539,348) | (1,050,000) | ||
| Proceeds from the sale of Infusionz and selected assets | - | 5,492,532 | ||
| Acquisition of property and equipment | (932,565) | (937,564) | ||
| Net cash provided by (used in) investing activities - Continuing Operations | 831,112 | (23,271) | ||
| Net cash (used in) investing activities - Discontinued Operations | (4,206,823) | (2,551,587) | ||
| Net cash used in investing activities | (3,375,711) | (2,574,858) | ||
| Cash flows from financing activities | ||||
| Repayment of the senior convertible notes payable | - | (6,305,406) | ||
| Proceeds from the issuance of stock | - | 6,127,893 | ||
| Payment on acquisition notes payable | (246,761) | (751,152) | ||
| Proceeds from related party advance | 100,000 | - | ||
| Proceeds from convertible note payable | - | 2,650,000 | ||
| Proceeds on note payable on building | - | 3,000,000 | ||
| Repayment on note payable on building | (207,028) | (158,434) | ||
| Proceeds on note payable, related party | - | 1,470,000 | ||
| Net cash (used in) provided by financing activities - Continuing Operations | (353,789) | 6,032,901 | ||
| Net cash used in financing activities - Discontinued Operations | - | (6,318,234) | ||
| Net cash used in financing activities | (353,789) | (285,333) | ||
| Net decrease in cash - Continuing Operations | (4,417,428) | (1,411,899) | ||
| Net (decrease) increase in cash - Discontinued Operations | 586,551 | (1,245,615) | ||
| Cash, beginning of period | 4,492,292 | 7,149,806 | ||
| Cash, end of period | $661,415 | $4,492,292 | ||
| Supplemental Cash Flow Disclosures | ||||
| Interest paid | $839,000 | $2,278,292 | ||
| Income tax paid | $ | - | $ | - |
| Non-cash Investing and Financing Activities | ||||
| Non-cash proceeds in the sale of VitaMedica | $1,900,000 | $ | - | |
| Issuance of common stock for acquisition of Cygnet | $162,727 | $ | - | |
| Issuance of debt for acquisition of Cygnet | $300,000 | $ | - | |
| Bloomios non-cash payment of receivables, net | $845,443 | $ | - | |
| Issuance of stock for services | $ | - | $140,700 | |
| Issuance of stock for interest expense | $ | - | $607,004 | |
| Issuance of common stock for the repayment of convertible note payable | $500,000 | $ | - | |
| Liabilities assumed from acquisition of E-Core | $ | - | $(7,712,168) | |
| Issuance of stock for acquisition of E-Core | $ | - | $6,000,000 | |
| Assets available for sale | $ | - | $1,026,043 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.